Cognition Disorders Clinical Trial
— CROVCDOfficial title:
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
| Verified date | January 2015 |
| Source | VA Office of Research and Development |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Federal Government |
| Study type | Interventional |
The number of OEF/OIF veterans seeking care and rehabilitation services within the VA Health Care System is increasing rapidly. The cognitive effects of MTBI are clinically significant and can adversely affect a veteran's ability to reintegrate into civilian life, return to duty, succeed in competitive employment, or function independently. The primary product of the proposed study would be an empirically validated, manualized, cognitive rehabilitation intervention for OIF/OIF veterans with cognitive disorders. The group treatment modality has the virtue of efficiency and a manualized treatment approach would allow wide-ranging application throughout the VHA system. As such, the proposed study is likely to have a significant effect on the quality and effectiveness of rehabilitative services being offered to our returning soldiers with combat-related MTBI and cognitive impairment.
| Status | Completed |
| Enrollment | 128 |
| Est. completion date | September 2013 |
| Est. primary completion date | May 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - OEF/OIF veterans enrolled at a participating VA who are able to provide informed consent; and - As part of standard VA clinical care, have screened positive for MTBI and complain of cognitive impairment. Exclusion Criteria: - Current substance use disorder with less than 30 days abstinence; - History of a primary psychotic disorder; and - Auditory or visual impairments that would prevent ability to participate in the cognitive rehabilitation group or benefit from compensatory strategies. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | VA Medical Center, Boise | Boise | Idaho |
| United States | VA Medical Center, Portland | Portland | Oregon |
| United States | VA San Diego Healthcare System, San Diego | San Diego | California |
| United States | VA Puget Sound Health Care System, Seattle | Seattle | Washington |
| Lead Sponsor | Collaborator |
|---|---|
| VA Office of Research and Development |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Multiple Sclerosis Neuropsychological Screening Questionnaire-Patient Version | A self-report measure of severity of attention and organizational problems. It measures the sum of severity ratings on a scale from 0 (never) to 4 (very often). The total score ranges from 0 to 64. | Week 10 | No |
| Secondary | Prospective-Retrospective Memory Questionnaire (PRMQ; Crawford, Henry, Ward, & | A 16-item self-report severity measure of prospective and retrospective memory problems relevant to everyday life. The measure reports the sum of severity ratings on a scale from 1 (never) to 5 (very often). The PRMQ total score ranges from 16 to 80. | Week 10 | No |
| Secondary | The Neurobehavioral Symptom Inventory | A post-concussive symptom measure. The total score on the measure is the sum of severity ratings for 22 symptoms on a scale from 0 (none) to 4 (very severe). NSI total score ranges from 0 to 88. | Week 10 | No |
| Secondary | Memory Compensation Questionnaire | The MCQ is a 44-item self-report questionnaire that rates the extent to which patients use various strategies to improve memory performance relevant to daily living. The MCQ measures the sum of memory strategies used on a scale from 0 (never) to 4 (always). The total score ranges from 0 to 176. | Week 10 | No |
| Secondary | Hopkins Verbal Memory Test-Revised | Verbal list learning and delayed recall. Total recall T-score was used for the analyses. Total recall T-score ranges from 13 (severely impaired) to 86 (very superior). | Week 10 | No |
| Secondary | Wechsler Adult Intelligence Scale-3rd Edition, Digit Span Subtest | A measure of attention and working memory. Total score was used, and it ranges from 0 to 48, with higher scores indicating greater attentional capacity. | Week 10 | No |
| Secondary | Delis-Kaplan Executive Function System, Trails Subtest | A visual-motor task used to measure flexibility in thinking (executive function) and processing speed. Scaled score for Condition 4 was used, and possible scores ranges from 0 to 20 with higher scores indicating better outcome. | Week 10 | No |
| Secondary | Delis-Kaplan Executive Function System, Verbal Fluency Subtest | A measure of verbal fluency, generativity, and processing speed. A scaled score of Letter Fluency portion of the test was used. The scores ranged from 0 to 20 with higher scores indicating better outcomes. | Week 10 | No |
| Secondary | PTSD Checklist-Military Version | A PTSD symptom severity measures based on DSM-IV diagnostic criteria. It measures the sum of severit ratings for 17 symptoms on a scale from 1 (not at all) to 5 (extremely). PCL-M total score ranges from 17 to 85. | Week 10 | No |
| Secondary | Beck Depression Inventory, Second Edition | A depression symptom severity measures based on DSM-IV diagnostic criteria. It measures the sum of severity ratings for 21 symptoms on a scale from 0 (none) to 3 (severe). BDI total score ranges from 0 to 63. | Week 10 | No |
| Secondary | Severity of Dependence Scale | A brief substance dependence measure. It measures the sum of severity ratings for 5 symptoms on a scale from 0 (never) to 3 (always). The total score ranges from 0 15. | Week 10 | No |
| Secondary | Satisfaction With Life Scale | A brief measure of global life satisfaction. It measures the sum of satisfaction ratings for 5 items on a scale from 1 (strongly disagree) to 7 (strongly agree). The total score ranges from 5 to 35 with higher scores indicating greater satifaction. | Week 10 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02488720 -
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
|
||
| Recruiting |
NCT03544801 -
Renji Cerebral Small Vessel Disease Corhort Study
|
||
| Recruiting |
NCT02813434 -
Cerebral Amyloid Imaging Using Florbetapir (AV-45)
|
Phase 3 | |
| Completed |
NCT00400790 -
Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane
|
N/A | |
| Completed |
NCT00052091 -
Therapy for Depressed Elders With Thought Problems
|
Phase 3 | |
| Completed |
NCT00267163 -
Brain Imaging and Mental Disorders of Aging Intervention
|
Phase 4 | |
| Completed |
NCT00021866 -
Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy
|
N/A | |
| Not yet recruiting |
NCT04079075 -
Multiple Interventions to Prevent Cognitive Decline
|
N/A | |
| Terminated |
NCT03696082 -
A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines
|
N/A | |
| Completed |
NCT02918539 -
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
|
||
| Active, not recruiting |
NCT01708837 -
Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction
|
Phase 4 | |
| Completed |
NCT01290939 -
Bevacizumab and Lomustine for Recurrent GBM
|
Phase 3 | |
| Terminated |
NCT00548327 -
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
|
Phase 2 | |
| Unknown status |
NCT00256425 -
Cognitive Rehabilitation of Glioma Patients
|
Phase 3 | |
| Recruiting |
NCT03926351 -
High Dose Omega 3 in People at Risk for Dementia
|
Phase 2 | |
| Completed |
NCT02118571 -
Schizophrenia Cognition Scale Development
|
N/A | |
| Completed |
NCT01481961 -
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease
|
N/A | |
| Completed |
NCT00788918 -
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
|
N/A | |
| Completed |
NCT00564902 -
The Zeaxanthin and Visual Function Study
|
N/A | |
| Completed |
NCT00529581 -
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
|
Phase 2 |